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Background
Temporomandibular Disorder (TMD) tends to coexist
with other chronic pain conditions in affected individuals
and is characterized by a report of pain greater than
expected based on the results of a standard physical eva-
luation. The pathophysiology of this condition is largely
unknown, the scientific field lacks biological markers for
accurate diagnosis, and conventional therapeutics have
limited effectiveness. Growing evidence suggests that
chronic pain conditions are associated with both physical
and psychological triggers, which initiate pain amplifica-
tion and psychological distress; thus, susceptibility is dic-
tated by complex interactions between genetic and
environmental factors [1].
Materials and methods
The large human study named OPPERA, Orofacial Pain
Prospective Evaluation and Risk Assessment Study, mea-
sures both phenotypic and genotypic markers in the TMD
patients. The phenotypic markers of greatest interest
include measures of pain amplification and psychological
measures such as emotional distress, somatic awareness,
psychosocial stress and catastrophizing. Genetic markers
are also measured in a study by genotyping 2,924 single-
nucleotide polymorphisms representing 358 genes known
to be involved in systems relevant to pain perception [1].
Results
The OPPERA findings provided evidence for few single
single-nucleotide polymorphisms to be associated with
risk of TMD [2]. Furthermore, several single-nucleotide
polymorphisms exceeded Bonferroni correction for multi-
ple comparison or false discovery rate thresholds for asso-
ciation with intermediate phenotypes shown to be
predictive of TMD onset [3] One of the genes on which
we focused our initial research efforts on was the epider-
mal growth factor receptor (EGFR). EGFR is activated by
numerous endogenous ligands that traditionally promote
cellular growth, proliferation and tissue regeneration. We
first identified that SNPs in the gene loci encoding for
EGFR and EREG are associated with the risk of chronic
TMD in OPPERA and two other independent human
cohorts. Subsequent experiments in animal models reveal
the functional involvement of these proteins in the pain
pathway, show pharmacological and genetic modulation of
pain behavior in rodents and Drosophila, and define the
relevant signaling pathway. EGFR–ErbB-4 heterodimer
activation by EREG produces pain by regulating the PI3K/
AKT/mTOR translational machinery and matrix metallo-
proteinase-9. As a result of these studies, EREG and
EGFR–ErbB-4 can be viewed as novel targets for analgesic
development.
Conclusions
Elucidation of the biological mechanisms by which these
markers contribute to the perception of pain in these
patients will enable the development of novel effective
drugs and methodologies that permit better diagnoses and
approaches to personalized medicine.
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